Glasgow, United Kingdom; 22nd October 2018: Sistemic Ltd. is pleased to announce the completion of a Global Service and License Agreement for its SistemPSCCheck™ assay with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd. The agreement will see the use of the SistemPSCCheck™ assay for the assessment of residual pluripotent stem cells in Cynata’s current iPSC-derived MSC clinical candidate CYP-001, as well other planned iPSC-derived MSC products.
We are looking for 2 life sciences graduates to support development of our new SistemPSCCheck™ v1.0 service product. These are 12 month placements, with the potential to develop into a permanent roles. For full information, please visit Scotgrad via the links below:
Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to highlight the development of SistemPSCCheck™ - the world’s first commercial assay for assessment of pluripotent stem cell contamination in derived cell therapy products
GLASGOW, SCOTLAND Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January to highlight the development of their assay for assessment of pluripotent stem cell contamination in derived cell therapy products
Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.